{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:04:52Z","timestamp":1787025892114,"version":"build-2736575974"},"reference-count":46,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2024,7,16]]},"abstract":"<jats:p>Background: Impact of Alzheimer\u2019s disease (AD) progression on patient health-related quality of life (HRQoL), caregiver time, and societal costs is not well characterized in early AD. Objective: To assess the association of change in cognition with HRQoL, caregiver time, and societal costs over 36 months, and estimate the impact of slowing disease progression on these outcomes. Methods: This post-hoc analysis included patients with amyloid-positive mild cognitive impairment (MCI) and mild AD dementia (MILD AD) from the 36-month GERAS-US study. Disease progression was assessed using the Mini-Mental State Examination score. Change in outcomes associated with slowing AD progression was estimated using coefficients from generalized linear models. Results: At baseline, 300 patients had MCI and 317 had MILD AD. Observed natural progression over 36 months was associated with: 5.1 point decline in the Bath Assessment of Subjective Quality of Life in Dementia (BASQID) score (for HRQoL), increase in 1,050\u200ahours of total caregiver time, and $8,504 total societal costs for MCI; 6.6 point decline in the BASQID score, increase in 1,929\u200ahours of total caregiver time, and $12,795 total societal costs for MILD AD per person. Slowing AD progression by 30% could result in per person savings in HRQoL decline, total caregiver time, and total societal costs: for MCI: 1.5 points, 315 hours, and $2,638; for MILD AD: 2.0 points, 579\u200ahours, and $3,974. Conclusions: Slowing AD progression over 36 months could slow decline in HRQoL and save caregiver time and societal cost in patients with MCI and MILD AD.<\/jats:p>","DOI":"10.3233\/jad-231166","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T12:48:46Z","timestamp":1718110126000},"page":"563-578","source":"Crossref","is-referenced-by-count":14,"title":["Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer\u2019s Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study"],"prefix":"10.1177","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4537-4025","authenticated-orcid":false,"given":"Julie M.","family":"Chandler","sequence":"first","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Ye","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Mi","sequence":"additional","affiliation":[{"name":"TechData Services Company, King of Prussia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin G.","family":"Doty","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-231166_ref1","doi-asserted-by":"crossref","unstructured":"(2023) 2023 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 19, 1598\u20131695.","DOI":"10.1002\/alz.13016"},{"key":"10.3233\/JAD-231166_ref2","first-page":"1","article-title":"Mortality in the United States, 2021","author":"Jiaquan Xu","year":"2022","journal-title":"NCHS Data Brief"},{"key":"10.3233\/JAD-231166_ref4","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1093\/ageing\/afab144","article-title":"Total cost of care increases significantly from early to mild Alzheimer\u2019s disease: 5-year ALSOVA follow-up","volume":"50","author":"Jetsonen","year":"2021","journal-title":"Age Ageing"},{"key":"10.3233\/JAD-231166_ref5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0039-1678581","article-title":"Current and future treatments in Alzheimer\u2019s disease","volume":"39","author":"Atri","year":"2019","journal-title":"Semin Neurol"},{"key":"10.3233\/JAD-231166_ref6","doi-asserted-by":"crossref","first-page":"173554","DOI":"10.1016\/j.ejphar.2020.173554","article-title":"Alzheimer\u2019s disease: Recent treatment strategies","volume":"887","author":"Vaz","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.3233\/JAD-231166_ref7","doi-asserted-by":"crossref","first-page":"e12179","DOI":"10.1002\/trc2.12179","article-title":"Alzheimer\u2019s disease drug development pipeline: 2021","volume":"7","author":"Cummings","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-231166_ref8","doi-asserted-by":"crossref","unstructured":"Haeberlein SB , Gheuens S , Chen T , O\u2019Gorman J , von Rosenstiel P , Chiao P , Wang G , von Hehn C , Skordos L , Hock C , Nitsch R , Sandrock (2018) Aducanumab 36-month data from PRIME: A randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer\u2019s disease (S2.004). Neurology 90(15_supplement), https:\/\/doi.org\/10.1212\/WNL.90.15_supplement.S2.004.","DOI":"10.1212\/WNL.90.15_supplement.S2.004"},{"key":"10.3233\/JAD-231166_ref9","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-231166_ref10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.3233\/JAD-231166_ref11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-231166_ref12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-beta plaques in patients with prodromal to moderate Alzheimer\u2019s disease: A PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-231166_ref15","doi-asserted-by":"crossref","unstructured":"Zhu CW , Sano M (2024) Meaningful benefit of disease modifying treatment: Evaluating changes in health related resource use. Alzheimers Dement (N Y).","DOI":"10.1002\/trc2.12455"},{"key":"10.3233\/JAD-231166_ref16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3233\/JAD-191212","article-title":"Costs of early stage Alzheimer\u2019s disease in the United States: Cross-sectional analysis of a prospective cohort study (GERAS-US)","volume":"75","author":"Robinson","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-231166_ref17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40120-021-00273-0","article-title":"Predicted lifetime health outcomes for aducanumab in patients with early Alzheimer\u2019s disease","volume":"10","author":"Herring","year":"2021","journal-title":"Neurol Ther"},{"key":"10.3233\/JAD-231166_ref18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40120-022-00350-y","article-title":"Long-term health outcomes of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther"},{"key":"10.3233\/JAD-231166_ref19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-231166_ref20","first-page":"197","article-title":"Two randomized phase 3 studies of Aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-231166_ref21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3233\/JAD-190430","article-title":"Observation of patient and caregiver burden associated with early Alzheimer\u2019s disease in the United States: Design and baseline findings of the GERAS-US cohort study","volume":"72","author":"Robinson","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-231166_ref22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/WAD.0b013e3181e2fc84","article-title":"Utility of the functional activities questionnaire for distinguishing mild cognitive impairment from very mild Alzheimer disease","volume":"24","author":"Teng","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-231166_ref23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JAD-231166_ref24","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/geront\/47.6.789","article-title":"How can we best assess the quality of life of people with dementia? the Bath Assessment of Subjective Quality of Life in Dementia (BASQID)","volume":"47","author":"Trigg","year":"2007","journal-title":"Gerontologist"},{"key":"10.3233\/JAD-231166_ref25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jalz.2012.06.008","article-title":"Application of Resource Utilization in Dementia (RUD) instrument in a global setting","volume":"9","author":"Wimo","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-231166_ref26","doi-asserted-by":"crossref","first-page":"e12430","DOI":"10.1002\/dad2.12430","article-title":"Disease progression and costs at the 3-year follow-up of the GERAS-US study","volume":"15","author":"Chandler","year":"2023","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-231166_ref27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12877-018-0748-9","article-title":"Potential cost savings to be made by slowing cognitive decline in mild Alzheimer\u2019s disease dementia using a model derived from the UK GERAS observational study","volume":"18","author":"Lenox-Smith","year":"2018","journal-title":"BMC Geriatr"},{"key":"10.3233\/JAD-231166_ref28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12877-016-0371-6","article-title":"Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer\u2019s disease: 18-month UK results from the GERAS observational study","volume":"16","author":"Lenox-Smith","year":"2016","journal-title":"BMC Geriatr"},{"key":"10.3233\/JAD-231166_ref30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13195-022-01075-8","article-title":"A longitudinal study on quality of life along the spectrum of Alzheimer\u2019s disease","volume":"14","author":"Mank","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-231166_ref31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2174\/1567205015666180119092427","article-title":"Estimating Alzheimer\u2019s disease progression rates from normal cognition through mild cognitive impairment and stages of dementia","volume":"15","author":"Davis","year":"2018","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-231166_ref32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/WAD.0000000000000124","article-title":"Predicting the rate of cognitive decline in Alzheimer disease: Data from the ICTUS Study","volume":"30","author":"Canevelli","year":"2016","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-231166_ref33","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3233\/ADR-210025","article-title":"Quality of life and caregiver burden of Alzheimer\u2019s disease among community dwelling patients in Europe: Variation by disease severity and progression","volume":"5","author":"Froelich","year":"2021","journal-title":"J Alzheimers Dis Rep"},{"key":"10.3233\/JAD-231166_ref34","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3233\/JAD-201514","article-title":"Impact of the severity of Alzheimer\u2019s disease on the quality of life, activities of daily living, and caregiving costs for institutionalized patients on anti-Alzheimer medications in Japan","volume":"81","author":"Ashizawa","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-231166_ref35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-022-00969-x","article-title":"Economic and caregiver impact of Alzheimer\u2019s disease across the disease spectrum: A cohort study","volume":"14","author":"Dauphinot","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-231166_ref36","first-page":"371","article-title":"Diagnosis of early Alzheimer\u2019s disease: Clinical practice in 2021","volume":"8","author":"Porsteinsson","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-231166_ref37","first-page":"PCC.10m01043","article-title":"The association between Alzheimer\u2019s disease symptom severity and caregiver outcomes: A cross-sectional study","volume":"13","author":"Kannan","year":"2011","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.3233\/JAD-231166_ref38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3928\/00989134-20220805-02","article-title":"Caregivers of adults living with Alzheimer\u2019s disease or dementia in 2020: A secondary analysis","volume":"48","author":"Shin","year":"2022","journal-title":"J Gerontol Nurs"},{"key":"10.3233\/JAD-231166_ref39","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2174\/1567205017666200102144640","article-title":"Cost of treatment and care for people with Alzheimer\u2019s disease: A meta-analysis","volume":"16","author":"Maresova","year":"2019","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-231166_ref40","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40258-013-0038-9","article-title":"Pre-diagnosis excess acute care costs in Alzheimer\u2019s patients among a US Medicaid population","volume":"11","author":"Geldmacher","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"key":"10.3233\/JAD-231166_ref41","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/jgs.14227","article-title":"Medicare expenditures of individuals with Alzheimer\u2019s disease and related dementias or mild cognitive impairment before and after diagnosis","volume":"64","author":"Lin","year":"2016","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-231166_ref42","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12877-018-0920-2","article-title":"Retrospective assessment of patient characteristics and healthcare costs prior to a diagnosis of Alzheimer\u2019s disease in an administrative claims database","volume":"18","author":"Nair","year":"2018","journal-title":"BMC Geriatr"},{"key":"10.3233\/JAD-231166_ref43","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/1403494815614705","article-title":"Hospital care and drug costs from five years before until two years after the diagnosis of Alzheimer\u2019s disease in a Finnish nationwide cohort","volume":"44","author":"Taipale","year":"2016","journal-title":"Scand J Public Health"},{"key":"10.3233\/JAD-231166_ref44","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.dadm.2018.12.005","article-title":"Trends in health service use and potentially avoidable hospitalizations before Alzheimer\u2019s disease diagnosis: A matched, retrospective study of US Medicare beneficiaries","volume":"11","author":"Desai","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-231166_ref45","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jalz.2015.01.007","article-title":"Direct medical costs and source of cost differences across the spectrum of cognitive decline: A population-based study","volume":"11","author":"Leibson","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-231166_ref46","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/gps.3819","article-title":"The effects of dependence and function on costs of care for Alzheimer\u2019s disease and mild cognitive impairment in Ireland","volume":"28","author":"Gillespie","year":"2013","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-231166_ref47","doi-asserted-by":"crossref","first-page":"37454","DOI":"10.52965\/001c.37454","article-title":"Impact of Alzheimer\u2019s disease on caregivers in the United States","volume":"10","author":"Vu","year":"2022","journal-title":"Health Psychol Res"},{"key":"10.3233\/JAD-231166_ref48","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.arr.2015.07.002","article-title":"Slowing the progression of Alzheimer\u2019s disease; what works?","volume":"23","author":"Nelson","year":"2015","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-231166_ref49","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41582-022-00645-6","article-title":"Early-stage Alzheimer disease: Getting trial-ready","volume":"18","author":"Aisen","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-231166_ref50","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s43587-022-00269-x","article-title":"Designing the next-generation clinical care pathway for Alzheimer\u2019s disease","volume":"2","author":"Hampel","year":"2022","journal-title":"Nat Aging"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-231166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:58:29Z","timestamp":1777370309000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-231166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":46,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-231166","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]}}}